Back to homepage

Gastroenterology

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications

Authors: Nicola Personeni MD, Tiziana Pressiani MD, Armando Santoro MD, Lorenza Rimassa MD

Over the past ten years, sorafenib has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) and in a second-line setting, most investigational drugs have failed to provide better survival outcomes than placebo. However, in 2016, data from the RESORCE trial, a phase 3 study evaluating regorafenib in HCC patients who experience disease progression after first-line treatment with sorafenib, have shown a 2.8-month median survival benefit over placebo (10.6 versus 7.8 months).

More▸

Treatment of diverticular disease: an update on latest evidence and clinical implications

Authors: Marilia Carabotti MD, PhD, Bruno Annibale MD

This article summarizes the latest evidence and clinical implication in treatment of diverticular disease focusing either on the treatment of diverticulosis, symptomatic uncomplicated diverticular disease and acute diverticulitis together with the primary and secondary prevention of diverticulitis.

More▸

Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE study)

Authors: Ignacio Marín-Jiménez MD, PhD, Cristina Saro MD, Verónica Díaz PhD, Manuel Barreiro-de Acosta MD, PhD, María Gómez-García MD, PhD, Ana Gutiérrez Casbas PhD, on behalf of the working group of EPICURE study

This article aims to assess the epidemiology of ulcerative colitis at hospital gastroenterology units and the use of hospital resources for the management of ulcerative colitis in Spain.

More▸

Synchronous GISTs associated with multiple sporadic tumors: a case report

Authors: Danila Comandini, Azzurra Damiani, Alessandro Pastorino

The authors report a case of primary prostate and lung tumors associated with gastric and small bowel GISTs, unrelated to any known hereditary syndrome.

More▸

Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy

Authors: Teerha Piratvisuth, Piyawat Komolmit, Henry LY Chan, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Mário G Pessoa, Eduardo Fassio, Suzane K Ono, Fernando Bessone, Jorge Daruich, Stefan Zeuzem, Michael Manns, Alkaz Uddin, Yuhong Dong, Aldo Trylesinski

Using data from a 2-year roadmap study, the authors concluded that telbivudine with add-on tenofovir was effective and well tolerated in patients with chronic hepatitis B, and that telbivudine was associated with an improvement in estimated glomerular filtration rate from baseline.

More▸